Bristol Myers Squibb’s Sotyktu recommended to treat adult patients with psoriasis on the NHS
The once-daily oral tablet will be available to patients whose Psoriasis Area and Severity Index (PASI) is ten or more and the Dermatology Life Quality Index (DLQI) is ten or more, and if their condition has not responded to other treatments including ciclosporin, methotrexate and phototherapy, or these treatments are contraindicated or not tolerated.
This NICE recommendation follows marketing authorisation in Great Britain in May 2023 for this indication.
Professor Chris Griffiths, emeritus professor at the University of Manchester, commented: “Today’s announcement marks another step forward for people with psoriasis. This complex condition can affect each person differently, therefore it is my hope that access to a greater variety of treatments, such as deucravacitinib, will enable eligible patients to have more choice, with therapies that may suit their daily needs and lifestyle.”
Laura Stevenson, deputy chief executive at Psoriasis Association, added: “It is estimated that psoriasis affects over a million people across the UK and for some, it can have a significant life impact. It is therefore hugely important for the community to have access to a variety of treatments, including new therapies such as deucravacitinib. The availability of deucravacitinib for adults with moderate-to-severe plaque psoriasis may make a real difference for eligible people with psoriasis and add to their potential treatment options. The Psoriasis Association is a national charity, here to provide patients with important new information as well as support with their condition.”